Clinical trials: Cerebral Circulatory Disorder
Brain Ischemia,Stoke
Dyslipidemia Management in Chinese Post Stroke Patients
The purpose of this study is to provide current and reliable data of dyslipidimia management together with control situation of blood pressure and glucose for post-stroke patients within 6-12 months from attack, and also the…
- Trial name
- NCT01897883
- Where
- 26 sites in China
- Volunteers
- 5,000 people
- Sponsor
- AstraZeneca
Atrial Fibrillation, Stroke
CHAMPION-AF Clinical Trial
The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial…
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- CHAMPION-AF (NCT04394546)
- Testing
- WATCHMAN FLX LAAC Device, Non-Vitamin K Oral Anticoagulant
- Where
- 141 sites in United States, Australia and 14 more
- Volunteers
- 3,000 people
- Sponsor
- Boston Scientific Corporation
Cerebral Stroke
Post Marketing Study to Evaluate the NIMBUS Device
A post-market study evaluating the NIMBUS Device in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
- Trial name
- SPERO (NCT03898960)
- Testing
- NIMBUS Device
- Where
- 2 sites in Germany, Sweden
- Volunteers
- 54 people
- Sponsor
- Neuravi Limited
Intracranial Aneurysms
Canadian eCLIPs™ Safety and Feasibility Study Protocol
The purpose of this study is to evaluate the safety and feasibility of the eCLIPs™ Family of Products for the treatment of unruptured intracranial bifurcation aneurysms in conjunction with embolization coils.
- Trial name
- CESIS (NCT01957683)
- Testing
- eCLIPs™ Family of Products
- Where
- 5 sites in Canada
- Sponsor
- Evasc Medical Systems Corp.
Stroke, Upper-limb Motor Impairment
Safety and Effectiveness of Spatial StimelMD (SSMD) in Subjects With Upper Limb Neuromotor Impairments
This is a multicenter, randomized, controlled clinical study evaluating the safety and effectiveness of the Spatial StimelMD (SSMD) device for upper-limb neuromotor rehabilitation in adults with impairment following stroke or…
- Conditions
- Stroke, Upper-limb Motor Impairment, Hemiparesis, Spinal Cord Injury
- Trial name
- NCT07404761
- Testing
- Spatial StimelMD (SSMD), Functional Electrical Stimulation (FES)
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Motion Informatics LTD
Stroke
AMPLATZER™ Amulet™ LAA Occluder Trial
The Amulet™ device will be evaluated for safety and efficacy by demonstrating its performance is non-inferior to the commercially available WATCHMAN® left atrial appendage closure device in patients with non-valvular atrial…
- Trial name
- Amulet IDE (NCT02879448)
- Testing
- Amulet Left Atrial Appendage Occluder, WATCHMAN Left Atrial Appendage Closure
- Where
- 115 sites in United States, Australia and 9 more
- Volunteers
- 1,878 people
- Sponsor
- Abbott Medical Devices
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment.
- Trial name
- CYPRESS (NCT05696717)
- Testing
- Ampreloxetine
- Where
- 79 sites in United States, Argentina and 18 more
- Volunteers
- 102 people
- Sponsor
- Theravance Biopharma
Intracranial Aneurysm, Flow Diverter
DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device
To analyse the clinical safety and efficacy of the DERIVO® 2heal® Embolisation Device in the standard clinical routine of flow diversion treatment with respect to the mid- and long-term clinical and angiographic outcomes.
- Trial name
- REheal (NCT05543447)
- Testing
- Flow Diverter Treatment with DERIVO 2 Heal Embolisation Device
- Where
- 17 sites in Germany
- Volunteers
- 158 people
- Sponsor
- Acandis GmbH
Carotid Artery Disease
Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease
The purpose of this study is to find the optimal dose from 3 different dose levels - 0.15 mL, 0.5 mL and 1.5 mL of Optison in assessing the presence of disease of the carotid arteries when comparing pre-contrast to post-contrast…
- Trial name
- NCT01394926
- Testing
- Optison
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- GE Healthcare
Cardiac Rhythm Disorders, Urological Disorders
Product Surveillance Registry
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products.
- Conditions
- Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
- Trial name
- PSR (NCT01524276)
- Where
- 402 sites in United States, Argentina and 39 more
- Volunteers
- 100,000 people
- Sponsor
- Medtronic
Cerebrovascular Accident, Hypercholesterolemia
Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke
The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.
- Trial name
- LA BICHAT (NCT00163150)
- Testing
- Atorvastatin
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke
Registry on WATCHMAN Outcomes in Real-Life Utilization
The WATCHMAN LAA Closure Technology is designed to prevent embolization of thrombi that may form in the LAA, thereby preventing the occurrence of ischemic stroke and systemic thromboembolism.
- Trial name
- EWOLUTION (NCT01972282)
- Testing
- WATCHMAN Left Atrial Appendage Closure
- Where
- 47 sites in Belgium, France and 11 more
- Volunteers
- 1,025 people
- Sponsor
- Boston Scientific Corporation
Aneurysm, AVM, Dural Arteriovenous Fistula, Glioma, Meningioma, Metastasis, Bypass
Intraoperative Laser Speckle Contrast Imaging of Cerebral Blood Flow
The purpose of the proposed study is to investigate the usefulness of laser speckle contrast imaging (LSCI) compared to indocyanine green angiography (ICGA).
- Trial name
- NCT05305378
- Testing
- Laser speckle contrast imaging (LSCI)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Dynamic Light
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-2 (NCT01975389)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,595 sites in United States, Argentina and 33 more
- Volunteers
- 10,564 people
- Sponsor
- Pfizer
Brain Diseases, Aneurysm
Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms
A registration trial of the Intracranial Visualized stent in the treatment of wide-necked intracranial aneurysms
- Conditions
- Brain Diseases, Aneurysm, Intracranial Aneurysm, Cardiovascular Diseases
- Trial name
- PROMISE (NCT05275296)
- Testing
- Intracranial stent for wide-necked aneurysms
- Where
- China
- Volunteers
- 200 people
- Sponsor
- MicroPort NeuroTech Co., Ltd.
Stroke, Ischemic Stroke
Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes
Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours…
- Conditions
- Stroke, Ischemic Stroke, Cerebrovascular Disorders, Brain Diseases
- Trial name
- GRASSROOT Reg (NCT07335185)
- Testing
- Supernova revascularization device
- Volunteers
- 3,000 people
- Sponsor
- Gravity Medical Technology, INC
Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.
- Trial name
- RESTORE (NCT06987643)
- Testing
- Neflamapimod
- Where
- 10 sites in Australia
- Volunteers
- 45 people
- Sponsor
- EIP Pharma Inc
Cerebral Infarction
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
The primary objective is to compare the safety of clopidogrel 50mg and 75mg in cerebral infarction with respect to incidence of bleeding adverse events.
- Trial name
- NCT00386191
- Testing
- clopidogrel (SR25990C)
- Where
- Japan
- Volunteers
- 1,110 people
- Sponsor
- Sanofi
Reconstructive Surgical Procedures, Plastic Surgery
Leica Microsystems Sponsored Study to Collect and Confirm Clinical Data on the Performance of the GLOW800 Device When Used in Accordance With Its Intended Use.
This post-market clinical follow-up (PMCF) study aims to confirm the safety and performance of the GLOW800 surgical microscope accessory when used in conjunction with the ARveo8x surgical microscope.
- Conditions
- Reconstructive Surgical Procedures, Plastic Surgery, Vascular Surgical Procedure, Cerebrovascular Disorder
- Trial name
- IMED-GLOW800 (NCT07164040)
- Testing
- The GLOW800, a non-contact, non-invasive device, allows the surgical microscope ARveo 8 and ARveo 8X to produce excitation light and resolve fluorescence emission from the fluorescent agent ICG
- Where
- 3 sites in Portugal, Spain and 1 more
- Volunteers
- 31 people
- Sponsor
- Leica Microsystems (Schweiz) AG
Cerebral Vasospasm
Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)
The objective of the study is to assess the safety and probable benefit of the Neva VS device in patients presenting with symptomatic cerebral vasospasm despite maximal medical management following aSAH.
- Trial name
- NCT03611790
- Testing
- NeVa VS
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vesalio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.